Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma : Episode 1
Brief Overview of Therapeutic Landscape for R/R MM
Panelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.
Video content above is prompted by the following:
- Provide a brief historical overview of the therapeutic landscape for R/R MM.
- How has the landscape evolved since, and what challenges/unmet needs remain?
- Comment on the recent updates surrounding the management of R/R MM with bispecifics:
- MonumenTAL-1: Long-Term Efficacy and Safety Results
- What does the long-term efficacy data from MonumenTAL-1 tell us about the durability of responses with talquetamab in heavily pretreated patients?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
